Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8986731 | 1.00 | BRD4 (0.55) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL2620988 | 1.00 | BRD4 (0.55) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| Hydrochloric Acid SCHEMBL8017393 | 0.98 | BRD4 (0.53) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| Dimethylamine SCHEMBL7484789 | 0.94 | BRD4 (0.50) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL21447810 | 0.80 | BRD4 (0.40) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL22953936 | 0.80 | BRD4 (0.51) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL15265894 | 0.79 | MTNR1A (0.47) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL31076159 | 0.79 | MTNR1A (0.47) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL2152470 | 0.79 | MTNR1A (0.47) | BRD4CREBBPMTNR1AMTNR1BEPHX2 | |
| SCHEMBL15265663 | 0.79 | MTNR1A (0.47) | BRD4CREBBPMTNR1AMTNR1BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019623-B1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2018-11-28 | — | — | EP | claimed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | claimed |
| EP-3019623-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | Euticals S.P.A. (IT) | 2016-05-18 | — | — | EP | claimed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | claimed |
| WO-2015004015-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2015-01-15 | — | — | WO | claimed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | claimed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3511323-B1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-03-02 | — | — | EP | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3019623-B1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017198149-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | 江苏豪森药业集团有限公司 | 2017-11-23 | — | — | WO | disclosed |
| WO-2017185959-A1 | FUSED IMIDAZOLE DERIVATIVES HAVING IDO/TDO INHIBITING ACTIVITY, AND PREPARATION METHOD AND USE THEREFOR | 江苏豪森药业集团有限公司 | 2017-11-02 | — | — | WO | disclosed |
| WO-2017128896-A1 | FXR AGONIST AND PREPARATION METHOD AND USE THEREOF | 江苏豪森药业集团有限公司 | 2017-08-03 | — | — | WO | disclosed |
| US-9163038-B2 | Process for synthesis of chiral 3-substituted tetrahydroquinoline derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-20 | — | — | US | disclosed |
| US-20150038714-A1 | Process for Synthesis of Chiral 3-Substituted Tetrahydroquinoline Derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-02-05 | — | — | US | disclosed |
| WO-2015004015-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004015-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2015-01-15 | — | — | WO | disclosed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | BRD4 528/4885CREBBP 1887/4885MTNR1A 853/4885 |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | CYP2S1, PRMT3, ARGLU1 | BRD4 1014/4885CREBBP 4741/4885MTNR1A 1216/4885 |
| US-20150038714-A1 | Process for Synthesis of Chiral 3-Substituted Tetrahydroquinoline Derivatives | TH, DHPS, QDPR | BRD4 1153/4885CREBBP 3036/4885MTNR1A 2182/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | BRD4 528/4885CREBBP 1887/4885MTNR1A 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.